Clinical Trails

A Phase II clinical trial suggests that a medically supervised ketogenic diet (MSKD) may help improve outcomes for patients with metastatic pancreatic ductal adenocarcinoma receiving combination chemotherapy with gemcitabine, nab-paclitaxel, and cisplatin. The study included 32 evaluable patients and compared chemotherapy plus the ketogenic diet with chemotherapy plus a usual diet. Results showed encouraging trends […]

EnteroBiotix has completed patient enrollment for its Phase 2a MAST trial, testing the oral microbiome therapy EBX-102-02 in patients undergoing allogeneic stem cell transplants. The therapy is given as a single dose before chemotherapy to protect the gut microbiome, which is often damaged during transplant and linked to complications like Graft-vs-Host Disease (GVHD) and infections.

A phase 1 trial shows that a venetoclax-based transplant regimen is safe and effective for high-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia patients. The study focused on older patients with poor-risk features, including TP53 mutations, using a reduced-intensity conditioning of venetoclax with fludarabine and busulfan, followed by post-transplant maintenance with venetoclax and oral decitabine/cedazuridine. Results

The first part of the global ProstACT study has shown that the radiopharmaceutical TLX591-Tx (Lutetium-177 rosopatamab tetraxetan) is safe and tolerable when combined with standard therapies for advanced prostate cancer. The trial involved 36 patients with PSMA-positive metastatic castration-resistant prostate cancer who had already progressed on a first androgen receptor pathway inhibitor. Each patient received

The PREP-02/JSAP05 trial showed that giving chemotherapy before surgery can improve survival for patients with Pancreatic Ductal Adenocarcinoma, the most common type of pancreatic cancer. In this study, researchers compared two treatment approaches. One group of patients had immediate surgery, while the other received chemotherapy with Gemcitabine and S-1 before surgery. After surgery, both groups

Can-Fite BioPharma announced that its Phase 2a trial of namodenoson (CF102) met its primary safety goal in patients with advanced Pancreatic Ductal Adenocarcinoma (PDAC). The study included 20 heavily pretreated patients whose disease had progressed after prior therapies. Namodenoson was well tolerated, with no new safety concerns, and its safety profile was consistent with previous

Results from the Phase 3 BREAKWATER trial suggest a new first-line treatment approach for metastatic colorectal cancer with the BRAF V600E mutation. Using targeted therapy early can significantly improve outcomes for patients with this aggressive form of cancer. The treatment combines encorafenib (Braftovi), cetuximab (Erbitux), and fluorouracil-based chemotherapy. In the trial, the combination achieved an

The Phase 3 KEYNOTE-B96 study shows that adding Pembrolizumab (Keytruda) to weekly paclitaxel, with or without bevacizumab, helps patients with platinum-resistant ovarian cancer live longer. This is the first immune checkpoint inhibitor regimen to significantly improve overall survival in this setting. Patients who received the combination lived a median of 17.7 months compared with 14.0

Immunotherapy has greatly improved treatment for advanced melanoma, but liver metastases remain a major challenge. The liver can act as an “immune sink,” where special immune cells destroy the T cells that are supposed to fight cancer. This weakens the body’s overall immune response and makes liver tumors especially hard to treat. In the CHOPIN

Researchers found that ovarian cancer cells quickly turn on a “pro-survival program” soon after treatment with PARP inhibitors begins. This fast response helps explain why these drugs can stop working, even if they seem effective at first. The team identified a protein called FRA1 as the key driver of this early resistance, allowing cancer cells